Schedule M rollout may face delay as MSMEs seek more time for upgrade

Q: How long will it take to read this news story?

The story "Schedule M rollout may face delay as MSMEs seek more time for upgrade" has 106 words across 4 sentences, which will take approximately 1 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Schedule M rollout may face delay as MSMEs seek more time for upgrade" was covered 7 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 309 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #28440038</li><li>URL: https://citrocola.beamstart.com/news/schedule-m-rollout-may-face-17465406692033</li></ul>

Business Standard Logo Business Standard 7h ago

Schedule M rollout may face delay as MSMEs seek more time for upgrade - Business Standard

Quick Summary:

Need More Information - write to us at assist@bsmail.

Small and medium-sized drugmakers have asked the Centre to extend the 10 May 2025 deadline to submit upgradation plans in line with the revised Schedule M by another three months, with experts raising concerns that further extensions could delay overall implementation.

This comes after the government, in February this year, granted small drug manufacturers with an annual turnover of less than Rs 250 crore a one-year extension to comply with the revised Schedule M, which specifies good manufacturing practices (GMPs) to ensure the quality of drugs made in the country.